Pre-clinical mouse studies demonstrate that the prophylactic administration of recombinant GM-CSF can be protective against IAV infection [47] and in patients, increased levels of GM-CSF during the early phase of ARDS is associated with improved prognosis [48]. The gene discussed is CSF2; the disease is acute respiratory distress syndrome.